• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCoronavirus

Fauci says he experienced ‘Paxlovid rebound’ but says the drug stopped his infection from becoming more severe

By
Erin Prater
Erin Prater
Down Arrow Button Icon
By
Erin Prater
Erin Prater
Down Arrow Button Icon
June 29, 2022, 4:09 PM ET
Updated June 29, 2022, 10:10 PM ET
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, attends a COVID federal response hearing on Capitol Hill on June 16.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, attends a COVID federal response hearing on Capitol Hill on June 16. Joe Raedle—Getty Images

Chief presidential medical adviser Dr. Anthony Fauci said this week that he experienced a so-called Paxlovid rebound after he took the antiviral to aid his recovery from COVID, but later clarified that the drug was important to his recovery. 

The symptoms he developed after he took the pill were more severe than those he had initially, he said.

“After I finished the five days of Paxlovid, I reverted to negative on an antigen test for three days in a row,” Fauci, 81, said during an event at Foreign Policy’s Global Health Forum, Bloomberg reported. “And then on the fourth day, just to be absolutely certain, I tested myself again.”

“I reverted back to positive,” he said. 

He then began a second course of Paxlovid when symptoms emerged “much worse than the first go-around,” he said. Fauci said he was feeling “reasonably good” as of Tuesday.

However, Fauci later told the New York Times that Paxlovid kept him away from the hospital, and stopped his infection from becoming more severe initially. “Paxlovid did what it was supposed to do,” he said in an interview with the outlet.

Paxlovid is a pill approved for treatment of COVID-19 in high-risk adults. It has emergency-use authorization from the U.S. Food and Drug Administration.

Fauci was prescribed Paxlovid owing to his advanced age, which puts him at greater risk for a severe outcome from COVID. He is fully vaccinated and twice boosted, Bloomberg reported.

Earlier this month Pfizer, which manufactures the medication, announced that it would stop adding new participants to a trial of the drug among COVID patients at low risk of hospitalization and death. The study failed to demonstrate that the drug reduced symptoms, or hospitalizations and deaths in a statistically significant way, according to Bloomberg.

The U.S. Centers for Disease Control and Prevention in May issued a health advisory regarding “COVID-19 rebound,” also known as “Paxlovid rebound.” 

But “a brief return of symptoms may be part of the natural history of SARS-CoV-2 (the virus that causes COVID-19) infection in some persons, independent of treatment with Paxlovid and regardless of vaccination status,” the advisory stated.

There is no evidence that additional treatment is needed for rebound cases, the CDC said in the advisory. It is unclear why Fauci took a second course of Paxlovid, in light of this guidance.
Patients who rebound after taking Paxlovid will need to isolate again for five days, according to the CDC. Such patients can report their rebound cases here.

June 29, 2022: This story has been updated to reflect additional comments that Dr. Anthony Fauci made about his Paxlovid treatment

Sign up for the Fortune Features email list so you don’t miss our biggest features, exclusive interviews, and investigations.

About the Author
By Erin Prater
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

Legion Whey+ Protein Powder Review (2026): Nutrition Expert Approved
HealthDietary Supplements
Legion Whey+ Protein Powder Review (2026): Nutrition Expert Approved
By Christina SnyderApril 9, 2026
22 hours ago
assis
CommentaryIBM
The digital sovereignty dilemma is a false choice — here’s how enterprises can have both
By Ana Paula AssisApril 9, 2026
1 day ago
Best Maca Root Supplements of 2026: Tester and Nutrition Expert Approved
HealthDietary Supplements
Best Maca Root Supplements of 2026: Tester and Nutrition Expert Approved
By Emily PharesApril 7, 2026
3 days ago
Photo of Marc Randolph
Successlifestyle
Netflix cofounder says he stopped work at 5 p.m. every Tuesday for 30 years to stay ‘sane,’ no matter the crisis: ‘Nothing got in the way of that’
By Emma BurleighApril 5, 2026
5 days ago
Peeps in yellow dye on a conveyor belt
HealthFood and drink
‘No one is saying, ‘I want more cancer with my candy”: Why Peeps are a ‘food chemical success story’ despite RFK Jr.’s campaign to destroy their dyes
By Catherina GioinoApril 5, 2026
5 days ago
6 Best Vitamins to Boost Energy (2026): Top Recommendations From Experts
HealthDietary Supplements
6 Best Vitamins to Boost Energy (2026): Top Recommendations From Experts
By Emily PharesApril 3, 2026
7 days ago

Most Popular

The U.S. government is spending $88 billion a month in interest on national debt—equal to spending on defense and education combined
Economy
The U.S. government is spending $88 billion a month in interest on national debt—equal to spending on defense and education combined
By Fortune EditorsApril 9, 2026
1 day ago
A Meta employee created a dashboard so coworkers can compete to be the company's No. 1 AI token user—and Zuckerberg doesn't even rank in the top 250
AI
A Meta employee created a dashboard so coworkers can compete to be the company's No. 1 AI token user—and Zuckerberg doesn't even rank in the top 250
By Fortune EditorsApril 9, 2026
1 day ago
Gen Z doesn't want your full-time job. They want several part-time roles, and it's reshaping the entire workforce
Success
Gen Z doesn't want your full-time job. They want several part-time roles, and it's reshaping the entire workforce
By Fortune EditorsApril 9, 2026
1 day ago
White-collar workers are quietly rebelling against AI as 80% outright refuse adoption mandates
AI
White-collar workers are quietly rebelling against AI as 80% outright refuse adoption mandates
By Fortune EditorsApril 9, 2026
1 day ago
'I hate working 5 days': Zoom CEO says traditional work schedules are becoming obsolete—and predicts a 3-day workweek by 2031
Success
'I hate working 5 days': Zoom CEO says traditional work schedules are becoming obsolete—and predicts a 3-day workweek by 2031
By Fortune EditorsApril 9, 2026
21 hours ago
Current price of oil as of April 9, 2026
Personal Finance
Current price of oil as of April 9, 2026
By Fortune EditorsApril 9, 2026
24 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.